Category: Pharma

1 2 10 / 13 POSTS
InSitu Biologics is an emerging biotech company focusing on development of AnestaGel™, a long-lasting and long-acting non-opiate painkiller. The sustained release drug AnestaGel is expected to be used in post-operative surgical procedures. Anesta ...
By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Financial UpdateOn July 23, 2018, MediciNova, Inc. (NASDAQ:MNOV) filed form 10-Q with financial results for the second quarter of 2018. As expected, the company did not report any rev ...
By David Bautz, PhD NYSE:OGEN READ THE FULL OGEN RESEARCH REPORT Oragenics, Inc. (NYSE:OGEN) is a biopharmaceutical company developing a new treatment for oral mucositis and novel antibiotic therapies for infectious diseases. The company’s lead devel ...
This week, John Vandermosten, Zacks’ Senior Biotech Analyst, speaks with CEO of ProMIS Neurosciences, Dr. Elliot Goldstein on CEO Money. ProMIS’ ticker is PMN on the Toronto Exchange and ARFXF here in the US. ProMIS is focused on finding a cure for A ...
John Vandermosten Senior Biotechnology Analyst Zacks Small Cap Research http://scr.zacks.com John Vandermosten is currently a senior biotechnology research analyst for Zacks Investment Research where he covers a portfolio of small cap biotechn ...
John Vandermosten Senior Biotechnology Analyst Zacks Small Cap Research http://scr.zacks.com 2017 Biotech/Pharma Year in Review Looking at healthcare overall, probably the biggest news of 2017 was related to the attempted repeal of the Affordabl ...
Dr. Ernest Bonner Dir. Of Research - Global Pharma Labs Inc. www.globalpharmalabs.net Global Pharma Labs Inc is a Regulation A Tier 2 company which is now accepting investors through its SEC qualified initial offering. Investors do not have to b ...
John Vandermosten Senior Biotechnology Analyst - Zacks Small Cap Research http://scr.zacks.com On today's show, Mr. Vandermosten discusses the opioid addiction crisis we are facing and one way to potentially address this issue: Abuse deterrent f ...
By John Vandermosten, CFANASDAQ:EGLTWe are initiating coverage of Egalet Corp. (NASDAQ:EGLT) with a $6.00 price target based on our estimates for growth of three products currently being commercialized in the United States.  Egalet has developed a th ...
Marc Fishman - CEO Oncology Analytics www.oncologyanalytics.com Oncology Analytics provides comprehensive oncology benefits management by providing end-to-end solutions for health plans that assure high-quality and high-value treatments for patie ...
1 2 10 / 13 POSTS